Ocular TherapeutixOCUL
OCUL
About: Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Employees: 274
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
138% more call options, than puts
Call options by funds: $5.14M | Put options by funds: $2.16M
119% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 16
9% more funds holding
Funds holding: 179 [Q4 2024] → 196 (+17) [Q1 2025]
1.25% more ownership
Funds ownership: 85.13% [Q4 2024] → 86.38% (+1.25%) [Q1 2025]
2% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 58
9% less funds holding in top 10
Funds holding in top 10: 11 [Q4 2024] → 10 (-1) [Q1 2025]
12% less capital invested
Capital invested by funds: $1.14B [Q4 2024] → $1.01B (-$136M) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$14
60%
upside
Avg. target
$15.33
76%
upside
High target
$17
95%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen | 72%upside $15 | Buy Reiterated | 29 May 2025 |
Needham Serge Belanger | 60%upside $14 | Buy Maintained | 6 May 2025 |
RBC Capital Luca Issi | 95%upside $17 | Outperform Initiated | 18 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Ocular Therapeutix™ to Participate in Upcoming Investor Conferences
BEDFORD, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor conferences in the second half of May 2025.
Negative
Zacks Investment Research
1 month ago
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.24 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to its newly appointed Executive Director, Payer Access, Thomas J. Cella, and one other newly hired non-executive employee. The awards were made as inducements material to the individual's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
2 months ago
Ocular Therapeutix™ to Participate in Two Investor Conferences in April
BEDFORD, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences in April:
Positive
The Motley Fool
3 months ago
Why Ocular Therapeutix Was Bumping Higher This Week
The market was seeing Ocular Therapeutix (OCUL -6.52%) very positively this week, and that sunny view pushed the company's stock higher.
Positive
Benzinga
3 months ago
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside
Needham initiated coverage on Ocular Therapeutix Inc OCUL, noting the company's lead asset, Axpaxli, an investigational axitinib-based intravitreal implant for wet age-related macular degeneration (wet AMD).
Positive
Seeking Alpha
3 months ago
Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential
Ocular Therapeutix focuses on Axpaxli, a long-acting wet AMD therapy administered every 6-12 months. Dextenza currently drives revenues, but Axpaxli is expected to unlock long-term growth. Ocular has two important Phase 3 trials (SOL-1 and SOL-R), which are key catalysts this year, with data expected by early 2026.
Neutral
Seeking Alpha
3 months ago
Ocular Therapeutix, Inc. (OCUL) Q4 2024 Earnings Call Transcript
Ocular Therapeutix, Inc. (OCUL) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
3 months ago
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.28 per share a year ago.
Neutral
GlobeNewsWire
3 months ago
Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025
BEDFORD, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss recent business progress and financial results for the fourth quarter and full year ended December 31, 2024.
Charts implemented using Lightweight Charts™